{
    "clinical_study": {
        "@rank": "26761", 
        "arm_group": {
            "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well trametinib and Akt inhibitor GSK2141795 work in\n      treating patients with acute myeloid leukemia. Trametinib and Akt inhibitor GSK2141795 may\n      stop the growth of cancer cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia", 
        "condition": [
            "Adult Acute Megakaryoblastic Leukemia (M7)", 
            "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", 
            "Adult Acute Monoblastic Leukemia (M5a)", 
            "Adult Acute Monocytic Leukemia (M5b)", 
            "Adult Acute Myeloblastic Leukemia With Maturation (M2)", 
            "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", 
            "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", 
            "Adult Acute Myeloid Leukemia With Del(5q)", 
            "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", 
            "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", 
            "Adult Acute Myelomonocytic Leukemia (M4)", 
            "Adult Erythroleukemia (M6a)", 
            "Adult Pure Erythroid Leukemia (M6b)", 
            "Recurrent Adult Acute Myeloid Leukemia", 
            "Untreated Adult Acute Myeloid Leukemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Leukemia", 
                "Leukemia, Erythroblastic, Acute", 
                "Leukemia, Megakaryoblastic, Acute", 
                "Leukemia, Monocytic, Acute", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelomonocytic, Acute", 
                "Leukemia, Myelomonocytic, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the proportion of patients achieving complete remission (CR) or CR with\n      incomplete recovery of platelets (CRp) as best response within 4 cycles of therapy of\n      trametinib in combination with GSK2141795 (Akt inhibitor GSK2141795) in acute myeloid\n      leukemia (AML) patients with retrovirus-associated deoxyribonucleic acid (DNA) sequence\n      (RAS) mutations.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the disease-free survival of patients achieving CR/CRp. II. To determine the\n      duration of response of patients achieving CR/CRp. III. To determine the toxicity profile of\n      trametinib in combination with GSK2141795 in this patient population.\n\n      IV. To determine the biologic effects of trametinib in combination with GSK2141795 on\n      leukemia cells.\n\n      OUTLINE:\n\n      Patients receive trametinib orally (PO) once daily (QD) and Akt inhibitor GSK2141795 PO QD\n      on days 1-28. Courses repeat every 28 days in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 12 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed AML, other than acute\n             promyelocytic leukemia, as defined by the 2008 World Health Organization (WHO)\n             criteria that have relapsed or refractory to standard chemotherapy; unsuitable for\n             standard chemotherapy or unwilling to undergo standard chemotherapy; subjects >= 60\n             years of age with newly diagnosed AML who are not candidates for or have refused\n             standard chemotherapy are eligible\n\n          -  Patients with prior autologous and allogeneic hematopoietic stem cell transplantation\n             are eligible if patients are off immunosuppression for > 1 month and have no evidence\n             of active graft versus host disease (GVHD) except grade 1 skin GVHD\n\n          -  Positive for RAS mutation (neuroblastoma RAS viral (v-ras) oncogene homolog [NRAS]\n             codon 12, 13, 61 mutation or v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog\n             [KRAS] codon 12, 13, 61 mutation) at a Clinical Laboratory Improvement Amendments\n             (CLIA)-certified laboratory prior to study entry; mutational testing will be\n             performed on bone marrow sample and/or peripheral blood; patients with previously\n             known RAS mutations prior to study entry may be considered positive for RAS mutation\n             for eligibility prior to a CLIA-certified laboratory confirmation of such a mutation\n             at the discretion of the investigator; (appropriate blood and/or bone marrow samples\n             must be taken for RAS determination and submitted to a CLIA-certified laboratory\n             prior to study entry); however, if such a mutation is not confirmed by the M D\n             Anderson Cancer Center (MDACC)/other center's CLIA-certified laboratory, the patient\n             may be permitted to stay on the study if they wish and consent to do so but such\n             patients' data will be analyzed separately\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)\n\n          -  Life expectancy of greater than 4 weeks\n\n          -  Able to swallow and retain orally-administered medication and does not have any\n             clinically significant gastrointestinal abnormalities that may alter absorption such\n             as malabsorption syndrome or major resection of the stomach or bowels\n\n          -  All prior treatment-related toxicities must be Common Terminology Criteria for\n             Adverse Events (CTCAE) version (v)4 grade =< 1 (except alopecia) prior to the first\n             dose of the study drug\n\n          -  Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (isolated\n             total bilirubin > 1.5 institutional ULN is acceptable if bilirubin is fractionated\n             and direct bilirubin is < 35%)\n\n          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x\n             institutional ULN\n\n          -  Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockroft-Gault\n             formula) >= 60 mL/min\n\n          -  Fasting serum glucose =< 150 mg/dl (fasting is defined as at least 8 hours without\n             oral intake)\n\n          -  Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal\n             (LLN) by echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n\n          -  Women of child-bearing potential and men must agree to use adequate contraception\n             (hormonal or barrier method of birth control; abstinence) prior to study, during the\n             study participation, and for four months after the last dose of drug; women of\n             child-bearing potential must have a negative serum pregnancy test within 14 days\n             prior to randomization and agree to use effective contraception throughout the\n             treatment period and for 4 months after the last dose of study treatment; should a\n             woman become pregnant or suspect she is pregnant while she or her partner is\n             participating in this study, she should inform her treating physician immediately\n\n          -  Ability to understand and the willingness to sign a written informed consent document\n\n        Exclusion Criteria:\n\n          -  History of another malignancy; exception: patients who have been disease-free for 3\n             years, or patients with a history of completely resected non-melanoma skin cancer\n             and/or patients with indolent secondary malignancies, are eligible; consult the\n             Cancer Therapy Evaluation Program (CTEP) Medical Monitor if unsure whether second\n             malignancies meet the requirements specified above\n\n          -  History of interstitial lung disease or pneumonitis\n\n          -  Any major surgery, extensive radiotherapy, chemotherapy with delayed toxicity,\n             biologic therapy, or immunotherapy within 21 days prior to randomization; daily or\n             weekly chemotherapy (with the exception of hydroxyurea) without the potential for\n             delayed toxicity within 14 days prior to randomization unless there is evidence of\n             rapidly progressive disease\n\n          -  Use of other investigational drugs within 28 days (or five half-lives, whichever is\n             shorter; with a minimum of 14 days from the last dose) preceding the first dose of\n             trametinib/GSK2141795 and during the study\n\n          -  Symptomatic or untreated leptomeningeal disease or brain metastases or spinal cord\n             compression\n\n          -  Patients with abnormal fasting glucose values at screening will be excluded; in\n             addition, patients with type 1 diabetes will also be excluded; however, patients with\n             type 2 diabetes will be allowed if diagnosed >= 6 months prior to enrollment, and if\n             presenting with regular hemoglobin A1C (HbA1C) =< 8% at screening\n\n          -  Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to trametinib or excipients or to dimethyl sulfoxide (DMSO) or\n             GSK2141795\n\n          -  Current use of a prohibited medication; the following medications or non-drug\n             therapies are prohibited:\n\n               -  Other anti-cancer therapy while on study treatment; (Note: megestrol [Megace] if\n                  used as an appetite stimulant is allowed)\n\n               -  Concurrent treatment with bisphosphonates is permitted; however, treatment must\n                  be initiated prior to the first dose of study therapy; prophylactic use of\n                  bisphosphonates in patients without bone disease is not permitted, except for\n                  the treatment of osteoporosis\n\n               -  The concurrent use of all herbal supplements is prohibited during the study\n                  (including, but not limited to, St. John's wort, kava, ephedra [ma huang],\n                  gingko biloba, dehydroepiandrosterone [DHEA], yohimbe, saw palmetto, or ginseng)\n\n                    -  Note: For proliferative disease, hydroxyurea will be allowed during weeks 1\n                       and 2 of cycle 1 of study; hydroxyurea may be started or the dose changed\n                       during that 2-week period if it is clinically indicated; if a subject not\n                       previously on a stable dose of hydroxyurea needs to begin hydroxyurea or a\n                       subject on a stable dose needs to have their dose increased during the\n                       first 2 weeks, the investigator will notify the clinical team that this has\n                       been initiated\n\n          -  In vitro data indicate that GSK2141795 is a cytochrome P450 family 3, subfamily A,\n             polypeptide 4 (CYP3A4) substrate; drugs that potently inhibit CYP3A4 could lead to\n             increased GSK2141795 exposure in subjects, and should either be prohibited or used\n             with caution; drugs which are strong inducers of CYP3A and may result in lower\n             exposures of GSK2141795 should also be prohibited; GSK2141795 also appears to be a\n             moderate in vitro inhibitor of CYP2C8 (50% inhibitory concentration [IC50] 3 mcM) and\n             CYP3A4 (IC50 11 mcM); drugs that are substrates of CYP3A4 or CYP2C8 with a narrow\n             therapeutic index may be prohibited; drugs that are sensitive substrates of CYP3A4 or\n             CYP2C8 should be used with caution; because the lists of these agents are constantly\n             changing, it is important to regularly consult a frequently-updated list; medical\n             reference texts such as the Physicians' Desk Reference may also provide this\n             information; as part of the enrollment/informed consent procedures, the patient will\n             be counseled on the risk of interactions with other agents, and what to do if new\n             medications need to be prescribed or if the patient is considering a new\n             over-the-counter medicine or herbal product\n\n          -  History or current evidence/risk of retinal vein occlusion (RVO)\n\n          -  History or evidence of cardiovascular risk including any of the following:\n\n               -  Left ventricular ejection fraction (LVEF) < institutional LLN\n\n               -  A QT interval corrected for heart rate using the Bazett's formula QTcB >= 480\n                  msec\n\n               -  History or evidence of current clinically significant uncontrolled arrhythmias\n                  (exception: patients with controlled atrial fibrillation for > 30 days prior to\n                  study dose are eligible)\n\n               -  Patient with symptomatic bradycardia, or a history of clinically significant\n                  bradyarrhythmias such as sick sinus syndrome, 2nd degree atrioventricular (AV)\n                  block (Mobitz type 2)\n\n               -  History of acute coronary syndromes (including myocardial infarction and\n                  unstable angina), coronary angioplasty, or stenting within 6 months prior to\n                  study dose\n\n               -  History or evidence of current >= class II congestive heart failure as defined\n                  by the New York Heart Association (NYHA) functional classification system\n\n               -  Treatment-refractory hypertension defined as a blood pressure of systolic > 140\n                  mmHg and/or diastolic > 90 mmHg which cannot be controlled by anti-hypertensive\n                  therapy\n\n               -  Patients with intra-cardiac defibrillators\n\n               -  Known cardiac metastases\n\n          -  Known active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the\n             exception of chronic or cleared HBV and HCV infection, are eligible); patients with\n             human immunodeficiency  virus (HIV) are not eligible if on anti-retroviral\n             medications\n\n          -  Any serious/and or unstable pre-existing medical disorder (aside from malignancy\n             exception above), psychiatric disorder, or other conditions that could interfere with\n             subject's safety, obtaining informed consent or compliance to the study procedures\n\n          -  Animal reproductive studies have not been conducted with trametinib and GSK2141795;\n             therefore, the study drug must not be administered to pregnant women or nursing\n             mothers; women of childbearing potential should be advised to avoid pregnancy and use\n             effective methods of contraception; men with a female partner of childbearing\n             potential must have either had a prior vasectomy or agree to use effective\n             contraception; if a female patient or a female partner of a patient becomes pregnant\n             while the patient receives trametinib/GSK2141795, the potential hazard to the fetus\n             should be explained to the patient and partner (as applicable)\n\n          -  HIV-positive patients on combination antiretroviral therapy are ineligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01907815", 
            "org_study_id": "NCI-2013-01354", 
            "secondary_id": [
                "NCI-2013-01354", 
                "2013-0001", 
                "9443", 
                "P30CA016672", 
                "N01CM00039"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
                "description": "Given PO", 
                "intervention_name": "Akt inhibitor GSK2141795", 
                "intervention_type": "Drug", 
                "other_name": "GSK2141795"
            }, 
            {
                "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
                "description": "Given PO", 
                "intervention_name": "trametinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "GSK1120212", 
                    "JTP-74057", 
                    "Mekinist"
                ]
            }, 
            {
                "arm_group_label": "Treatment (trametinib, Akt inhibitor GSK2141795)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "todenike@medicine.bsd.uchicago.edu", 
                    "last_name": "Olatoyosi M. Odenike", 
                    "phone": "773-702-3354"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Olatoyosi M. Odenike", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mbaer@umm.edu", 
                    "last_name": "Maria R. Baer", 
                    "phone": "410-328-8708"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland/Greenebaum Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Maria R. Baer", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "njain@mdanderson.org", 
                    "last_name": "Nitin Jain", 
                    "phone": "713-745-6080"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "M D Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Nitin Jain", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rwalter@fhrcc.org", 
                    "last_name": "Roland B. Walter", 
                    "phone": "206-667-3599"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "Roland B. Walter", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations", 
        "other_outcome": [
            {
                "description": "Change in total and phospho-proteins assessed by densitometric quantitative data by western blot analysis, or mean fluorescent intensities by flow cytometry and will be assessed for each patient for all time points and graphically plotted for each dose level.", 
                "measure": "Maximum percentage change in total and phospho-proteins", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 12 weeks post therapy"
            }, 
            {
                "description": "The 95% confidence interval will be assessed.", 
                "measure": "Percentage change in cellular proteins", 
                "safety_issue": "No", 
                "time_frame": "Baseline to day 28 post treatment"
            }
        ], 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Nitin Jain", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The chi-square test or the Fisher's exact test will be applied to assess the association between categorical variables. 95% confidence interval will be estimated for the combination regimen.", 
            "measure": "Complete response rate (CRR, defined as CR+CRp) assessed by the Response Evaluation Criteria in Solid Tumors", 
            "safety_issue": "No", 
            "time_frame": "Up to 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01907815"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "description": "Toxicity data will be summarized using frequency tables by AE severity and by relationship to study drug. Toxicity rate with 95% credible interval will be estimated for the combination regimen.", 
                "measure": "Incidence of adverse events (AE) assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}